Kovitz Investment Group Partners, LLC released its second-quarter 2025 investor letter, reporting a 7.9% return for its Kovitz Core Equity Strategy, lower than the S&P 500’s 10.9%. The market experienced volatility after the President’s tariff announcement, with the S&P 500 initially dropping 11% but later rallying 25% after the tariffs were postponed.

In the same letter, Kovitz Core Equity Strategy highlighted Becton, Dickinson and Company (NYSE:BDX), a healthcare company. BDX had a one-month return of 0.79% and shares lost 23.96% over the last 52 weeks, closing at $176.89 per share on August 5, 2025, with a market cap of $50.698 billion.

The investor letter discussed BDX’s stock decline due to lower-than-expected revenue growth, earnings exceeding expectations, and analysts downgrading recommendations. Despite uncertainties, the company’s solid fundamentals and market position were emphasized, leading to confidence in the stock’s valuation and future growth potential.

Becton, Dickinson, and Company (NYSE:BDX) is not among the 30 Most Popular Stocks Among Hedge Funds, with 54 hedge funds holding the stock at the end of the first quarter. While BDX has investment potential, other AI stocks may offer greater upside potential. Investors seeking undervalued AI stocks can explore free reports for more opportunities.

For additional insights on BDX and stock recommendations, refer to Grok’s stock advice and hedge fund investor letters for Q2 2025. Explore more articles on the best and worst Dow stocks for the next 12 months and unstoppable stocks that could double your money. This article was originally published by Insider Monkey.

Read more at Yahoo Finance: Becton Dickinson (BDX) Fell Due to Decline in Organic Revenue Growth